Purple Biotech (PPBT) Equity Ratio (2018 - 2021)

Purple Biotech (PPBT) has disclosed Equity Ratio for 4 consecutive years, with 0.93 as the latest value for Q4 2021.

  • On a quarterly basis, Equity Ratio fell 2.54% to 0.93 in Q4 2021 year-over-year; TTM through Dec 2021 was 0.93, a 2.54% decrease, with the full-year FY2021 number at 0.93, down 2.54% from a year prior.
  • Equity Ratio was 0.93 for Q4 2021 at Purple Biotech, down from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q4 2020 to a low of 0.74 in Q4 2019.
  • A 4-year average of 0.84 and a median of 0.84 in 2018 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: rose 28.99% in 2020, then fell 2.54% in 2021.
  • Purple Biotech's Equity Ratio stood at 0.75 in 2018, then fell by 1.28% to 0.74 in 2019, then increased by 28.99% to 0.95 in 2020, then decreased by 2.54% to 0.93 in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Equity Ratio are 0.93 (Q4 2021), 0.95 (Q4 2020), and 0.74 (Q4 2019).